Page last updated: 2024-08-24

atorvastatin and Aberrant Crypt Foci

atorvastatin has been researched along with Aberrant Crypt Foci in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Chang, WL; Clapper, ML; Cooper, HS1
Benya, R; Chiorean, M; Della'Zanna, G; Gostout, C; Heigh, R; Lawson, MJ; Levine, J; Limburg, PJ; Mahoney, MR; Mandrekar, SJ; Richmond, E; Rodriguez, L; Schoen, RE; Smyrk, TC; Sontag, SJ; Stoffel, E; Weinberg, DS; Ziegler, KL1

Reviews

1 review(s) available for atorvastatin and Aberrant Crypt Foci

ArticleYear
Dysplastic Aberrant Crypt Foci: Biomarkers of Early Colorectal Neoplasia and Response to Preventive Intervention.
    Cancer prevention research (Philadelphia, Pa.), 2020, Volume: 13, Issue:3

    Topics: Aberrant Crypt Foci; Adenoma; Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents; Aspirin; Atorvastatin; Carcinogenesis; Catechin; Clinical Trials as Topic; Colon; Colonoscopy; Colorectal Neoplasms; Dietary Supplements; Disease Models, Animal; Humans; Intestinal Mucosa; Lycopene; Mice; Mutation; Treatment Outcome

2020

Trials

1 trial(s) available for atorvastatin and Aberrant Crypt Foci

ArticleYear
Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.
    Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:2

    Topics: Aberrant Crypt Foci; Aged; Antineoplastic Agents; Atorvastatin; Colorectal Neoplasms; Dietary Fiber; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Male; Middle Aged; Pyrroles; Sulindac; Survival Rate; Treatment Outcome

2011